Testing silevertinib added to temozolomide for newly diagnosed glioblastoma
Original title: Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing whether adding a drug called silevertinib to temozolomide works better than temozolomide alone.
Who this trial is for. This trial is for people with newly diagnosed glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, a type of brain tumor. It is for people whose tumor has an unmethylated MGMT marker and an EGFRvIII marker. It tests silevertinib combined with temozolomide after surgery and radiation, compared with temozolomide alone.
Where it stands. This trial has not reported results. The team is still working out how much of the study drugs to give. They are watching for side effects. They are also measuring whether the combination helps people live longer without the tumor getting worse than temozolomide alone does. The answers are not in yet.
What this means, and what it doesn't
What it could mean: If your tumor has these markers, this is one option you could ask your care team about. Your team can tell you if it fits your situation.
What it doesn't mean: This does not mean silevertinib is a proven treatment. A trial is a test. Researchers do not yet know if it helps. Joining a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.